Bolt Biotherapeutics’ (BOLT) Neutral Rating Reiterated at HC Wainwright

Bolt Biotherapeutics (NASDAQ:BOLT)‘s stock had its “neutral” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports.

Separately, Stifel Nicolaus reduced their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research report on Tuesday. Five analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Stock Performance

Shares of NASDAQ:BOLT traded up $0.00 during midday trading on Tuesday, reaching $0.44. 197,162 shares of the company’s stock traded hands, compared to its average volume of 119,987. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. Bolt Biotherapeutics has a one year low of $0.38 and a one year high of $1.56. The company has a market cap of $16.88 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The stock has a 50 day moving average of $0.47 and a 200 day moving average of $0.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. As a group, equities research analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BOLT. FMR LLC raised its position in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at approximately $42,000. Velan Capital Investment Management LP purchased a new stake in Bolt Biotherapeutics during the 4th quarter valued at $27,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth $26,000. Finally, Millennium Management LLC purchased a new position in Bolt Biotherapeutics during the fourth quarter worth $25,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.